# Abbott Launches Ultreon™ 3.0 In Brazil, Next-Generation AI-Powered Coronary Imaging Platform

- Technology combines high-resolution intracoronary imaging and AI-automated insights to support faster and more precise decision-making during Percutaneous Coronary Intervention (PCI)
- Coronary artery disease is among the leading causes of mortality in Brazil[1]

SÃO PAULO, Nov. 23, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, announced the launch of Ultreon™ 3.0 in Brazil, the latest generation of its optical coherence tomography (OCT) intracoronary imaging platform powered by artificial intelligence (AI). Designed to support physicians during minimally invasive procedures used to treat blocked coronary arteries, the technology combines high-resolution intracoronary imaging with AI-powered analysis in a single system, providing real-time guidance to support clinical decision-making during the treatment of complex coronary artery disease.

**What is Ultreon 3.0?**

Ultreon 3.0 is an AI-powered intravascular imaging platform that uses optical coherence tomography (OCT) to provide physicians with a detailed view of the coronary arteries during percutaneous coronary intervention (PCI), a procedure used to restore blood flow in blocked arteries.

The platform combines high-resolution imaging and advanced artificial intelligence capabilities to help physicians assess the characteristics of coronary blockages for treatment planning, which can lead to better results for patients.

**How does the technology work?**

The system uses OCT images to visualize the detailed structure of the artery and the plaque responsible for the blockage. Supported by artificial intelligence, the platform automatically analyzes the characteristics of the coronary lesion, providing information that helps physicians determine appropriate stent sizing and placement during PCI to support vessel patency and blood flow.

Ultreon 3.0 was designed to integrate all this information into a single, intuitive workflow, enabling fast decision-making during procedures.

**What's new in Ultreon 3.0?**

Building on the evolution of the platform first launched in Brazil in 2023, Ultreon 3.0 incorporates new AI capabilities and features designed to streamline physicians' workflow.

Key enhancements include:

- Integration of high-resolution coronary imaging and AI-automated insights into a single platform;
- Detailed assessment of the size, shape, and location of arterial blockages;
- Support for more accurate stent sizing and positioning;
- Post-procedure assessment to help confirm proper stent expansion and improved blood flow;
- Streamlined workflow with advanced automation features;
- Ultra-fast OCT image acquisition, capable of capturing detailed images of the coronary artery in just one second, supporting both procedure planning and assessment;
- Low or zero contrast required for image acquisition. *

*Reducing the amount of contrast may be particularly beneficial for some patients with kidney disease, who represent approximately 25% of people with coronary artery disease.[2]

"Ultreon 3.0 represents an important advancement in the way intracoronary imaging is used during coronary interventions. By bringing relevant information together in a single platform and presenting it quickly and intuitively, the technology helps specialists make clinical decisions with greater confidence when it matters most," said Louis Nakayama Ohe, M.D., head of the Hemodynamics Section at Dante Pazzanese Institute of Cardiology.

**How can Ultreon 3.0 contribute to patient care?**

By combining detailed coronary artery imaging with AI-powered automated analysis, Ultreon 3.0 helps physicians better understand the characteristics of each arterial blockage and make more informed decisions throughout the procedure.

"Ultreon 3.0 represents an important evolution in the use of artificial intelligence and intravascular imaging to support clinical decision-making during coronary procedures. By providing physicians with a more detailed view of the coronary arteries and real-time automated analysis, the platform contributes to more precise treatment planning. Our goal is to help specialists make decisions with greater confidence during complex procedures, contributing to increasingly personalized and effective patient care," said Mara Rinaldi, general manager of Abbott's vascular business in Brazil.

**Why are advanced imaging technologies important in the treatment of coronary artery disease?**

Coronary artery disease is among the leading causes of mortality in Brazil and worldwide. In Brazil, cardiovascular diseases cause approximately 300,000 deaths annually, with coronary artery disease accounting for about one-third of these deaths.[1] Many patients present with complex lesions that require a high degree of precision during the planning and execution of percutaneous coronary interventions.

In this context, advanced imaging technologies help physicians obtain detailed information about arterial structures and coronary blockages before, during, and after the procedure, supporting more precise clinical decision-making.

"The launch of Ultreon 3.0 in Brazil represents an advancement for interventional cardiology. The integration of high-resolution intracoronary imaging, physiological assessment and artificial intelligence into a single platform allows for a better understanding of coronary artery disease and more precise decision-making during the procedure. With faster image acquisition, reduced contrast use and automated analysis tools, we are taking an important step toward more efficient and personalized procedures. The differentiating factor of this technology is not only its ability to provide a clearer view of the artery, but also to transform this information into decisions that can improve the treatment of our patients," said Carlos Campos, M.D., physician in the Interventional Cardiology Department at InCor.

**About Abbott:**

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritional and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.

Abbott has been present in Brazil for almost 90 years and its local strategy is aimed at providing people with better access to innovative and affordable health solutions, contributing to the healthcare development in the country. In Brazil, the company has approximately 2,800 employees with primary locations in São Paulo (headquarters), Rio de Janeiro and Belo Horizonte (manufacturing site).

Connect with us at www.abbottbrasil.com.br, on LinkedIn, Facebook, Instagram, X and YouTube.

**References**


1. Ralapanawa U, Sivakanesan R. *Epidemiology and the Magnitude of Coronary Artery Disease and Acute Coronary Syndrome: A Narrative Review* J Epidemiol Glob Health. 2021;11(2):169-177. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC8242111/
2. Mehdi, A., Taliercio, J. J., & Nakhoul, G. (November 1, 2020).*Contrast Media in Patients with Kidney Disease: An Update* Cleveland Clinic Journal of Medicine. Available at: https://www.ccjm.org/content/87/11/683#:~:text=Nevertheless%2C%20CI%2DAKI%20remains%20real,24%25%20of%20patients%2C%20respectively


*The opinions and experiences expressed herein do not necessarily reflect the views of Abbott.
OPTIS™ Mobile Next – ANVISA Registration No. 10332340482
CAUTION: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events, and directions for use.

™ Indicates a trademark of Abbott.


Abbott
St. Jude Medical Brasil Ltda.
Rua Itapeva, 538 – 5th to 8th Floors
Bela Vista – São Paulo – SP 01332-000 – Brazil


© 2026 Abbott. All rights reserved. | Item approved for use in Brazil only.



For further information: Abbott Media: Marina Lima, marinadelima.silva@abbott.com or Priscila Martins, priscila.martins@abbott.com